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The target of rapamycin (TOR), a central controller of
cell growth, is found in two distinct, highly conserved
multiprotein complexes. Three recent papers in Cell
(Jacinto et al., 2006), Developmental Cell (Shiota
et al., 2006; this issue), and Current Biology (Frias
et al., 2006) shed light on mTOR complex 2 (mTORC2)
composition and in vivo function. An important new
finding is that mTORC2 determines Akt/PKB substrate
specificity rather than absolute activity.
Cell growth, along with cell division and cell death, is one
of the most fundamental aspects of cell behavior. Cell
growth is controlled by the two structurally and function-
ally distinct TOR complexes TORC1 and TORC2 (Wulls-
chleger et al., 2006). These protein kinase complexes,
first discovered in yeast, are highly conserved in eukary-
otes. The mammalian TORCs (mTORCs) activate cell
growth in response to nutrients, growth factors, and cel-
lular energy. Both mTORC1 and mTORC2 contain the
ser/thr kinase mTOR and the small Gb-like protein
mLST8. In addition, mTORC1 specifically contains rap-
tor, while mTORC2 specifically contains rictor and
mSIN1 (also known as SIN1, hSIN1, or MIP1). mSIN1,
an ortholog of the TORC2 member AVO1 in yeast and
Rip3 in Dictyostelium, is a newly described component
of mTORC2 (Frias et al., 2006; Jacinto et al., 2006).
mTORC1, the target of the immunosuppressive and an-
ticancer drug rapamycin, controls protein synthesis via
its two well-characterized effectors S6 kinase (S6K)
and the translational repressor 4E-BP1. mTORC2, on
the other hand, has no known specific inhibitor and
was discovered only recently (Jacinto et al., 2004; Sar-
bassov et al., 2004). RNAi-mediated knockdown of rictor
in cultured cells has shown that mTORC2 controls actin
cytoskeleton organization (Jacinto et al., 2004; Sarbas-
sov et al., 2004) and also directly phosphorylates and
activates Akt/PKB (Sarbassov et al., 2005).
Akt/PKB, a particularly famous member of the AGC
protein kinase family, controls metabolism, prolifera-
tion, cell survival, and other readouts. Full activation of
Akt/PKB involves its recruitment to the plasma mem-
brane, where it is phosphorylated on Ser473 in the
hydrophobic motif by mTORC2, and on Thr308 in the
activation loop by PDK1. There is longstanding dis-
agreement on whether phosphorylation of Ser473 is
a prerequisite for phosphorylation of Thr308 or Thr308
phosphorylation is independent of Ser473.
Jacinto, Su, and coworkers (Jacinto et al., 2006) and
Magnuson and coworkers (Shiota et al., 2006) knocked
out mSIN1 and rictor, respectively, to further elucidate
mTORC2 function and in particular the role of mTORC2
in the regulation of Akt/PKB. Shiota et al. (2006) first
replaced part of the wild-type rictorgene with a lacZ cas-
sette, which enabled them to visualize rictor expression
in whole animals. They found high and ubiquitous ex-pression of LacZ (rictor) in mouse embryos. LacZ was
also widespread in adult mice, with strongest expression
in testis and neurons. They then observed that rictor2/2
embryos at day E9.5 were smaller than wild-type em-
bryos and died by day E11.5. Although no major struc-
tural defect in any organ system was found, cellular de-
generation, including nuclear swelling and formation of
vacuoles, was observed. The embryos also showed pla-
cental defects; however, expression of rictor in the pla-
centa did not restore viability, indicating that placental
defects alone were not the cause of the embryonic lethal-
ity. Knockout ofmTOR, as reported previously, results in
significantly earlier embryonic lethality (Gangloff et al.,
2004; Murakami et al., 2004), suggesting that mTORC1
also has an essential role early in development. An
mTORC1-specific knockout has yet to be reported.
Jacinto et al. (2006) and Frias et al. (2006), in agree-
ment with earlier findings in yeast (Wullschleger et al.,
2006), demonstrated that mSIN1 is a member of
mTORC2 in mammals. Frias et al. (2006) also showed
that three of five known mSIN1 isoforms can assemble
into mTORC2. Jacinto et al. (2006) then disrupted the
mSIN1 gene in mice. Knockout of mSIN1, like knockout
of rictor, resulted in embryonic lethality; however, fur-
ther details on the embryonic lethality of the mSIN1
knockout remain to be reported. Thus, like their coun-
terparts in yeast, both rictor and mSIN1 are essential.
To further examine mTORC2 function, Jacinto et al.
(2006) and Shiota et al. (2006) isolated MEFs from rictor
or mSIN1 null embryos. As expected, both found that
knockout of mTORC2 inhibited phosphorylation of
Ser473 in Akt/PKB, suggesting that mTORC2 is the
Ser473 kinase. Although the two studies are in remark-
able agreement, there are some minor differences. The
most noteworthy is that Shiota et al. (2006) observed re-
sidual Akt/PKB Ser473 phosphorylation in rictor null
MEFs, whereas Jacinto et al. (2006) found that Ser473
phosphorylation was completely abolished in mSIN1
null MEFs. This difference could be due to different
growth conditions, different genetic backgrounds, or
the fact that different mTORC2 subunits were knocked
out. However, residual Ser473 phosphorylation in the
absence of intact mTORC2 suggests that another
kinase(s), such as DNA-PK (Feng et al., 2004), is able
to phosphorylate Ser473.
Knockout of mTORC2 resulted in loss of Ser473 phos-
phorylation, but no difference in the phosphorylation of
Akt/PKB Thr308. Importantly, this suggests that Thr308
phosphorylation is independent of Ser473 phosphoryla-
tion. But, is Akt/PKB active when phosphorylated only
on Thr308? Both groups examined several well-known
Akt/PKB-dependent phosphorylation targets, including
GSK3, TSC2, mTOR, and S6K, and found that mTORC2
knockout had no effect. The only targets affected were
the Forkhead transcription factors FoxO1 and FoxO3,
whose phosphorylation was strongly reduced in mSIN1
null MEFs. This finding is in agreement with a previous
report that FoxO4 phosphorylation is reduced upon
knockdown of rictor (Sarbassov et al., 2005). These
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the fact that most but not all Akt/PKB targets are still
phosphorylated in mTORC2 knockout MEFs suggests
that Ser473 phosphorylation determines Akt/PKB spec-
ificity rather than absolute activity. Second, since reduc-
tion in FoxO phosphorylation is the only observed Akt/
PKB signaling defect, does this defect alone account
for the embryonic lethality? Akt/PKB negatively regu-
lates FoxO. Reduced FoxO phosphorylation should
therefore lead to FoxO hyperactivation. FoxO transcrip-
tion factors control various target genes in a tissue-
dependent manner. It would be of interest to determine
which FoxO target genes are affected in the mTORC2
knockout MEFs, and to test whether disruption of
FoxO rescues the mTORC2-disrupted mice. Obviously,
it would also be of interest to look for other abnormalities
in the mTORC2-disrupted mice that might account
for the embryonic lethality. Third, the finding that Akt/
PKB Ser473 phosphorylation is not necessary for phos-
phorylation of TSC2, mTOR, and S6K solves a puzzle.
mTORC2 was assumed to regulate Akt/PKB activity
toward all its substrates, including TSC2, which nega-
tively regulates mTORC1. Thus, mTORC2 should acti-
vate mTORC1. However, contrary to this assumption,
mTORC2 knockdown was previously shown not to affect
the mTORC1 target S6K (Jacinto et al., 2004; Sarbassov
et al., 2004). We now know that Ser473 phosphorylation
is not required for Akt/PKB to signal to mTORC1. Thus,
mTORC2 is not upstream of mTORC1.
mTORC2, like yeast and Dictyostelium TORC2, has
been shown to regulate actin cytoskeleton organization.
However, Shiota et al. (2006) failed to observe an actin
defect in the rictor knockout MEFs. Shiota et al. (2006)
also point out that the rictor knockout mice seemed to
develop normally until day E9.5, including gastrulation,
neurulation, and formation of the cardiovascular sys-
tem—all of which require an intact actin cytoskeleton.
This could indicate that mTORC2 is not necessary for
regulation of actin cytoskeleton organization in vivo.
Still, actin defects following TORC2 disruption have
been detected in all organisms examined. It is possibleDevelopmental Cell 11, October, 2006 ª2006 Elsevier Inc. DOI 10.1016
Found in Translation:
A New Player in EMT
Epithelial mesenchymal transition (EMT) is a complex
process that involves changes in gene expression,
cytoskeleton organization, cell adhesion, and extra-
cellular matrix composition. Screening for genes
mediating EMT and cancer metastasis, Waerner, Ala-
cakaptan, and colleagues identified ILEI, a cytokine-
like protein that plays an essential role in EMT, tumor
growth, and late steps of metastasis.
Epithelial and mesenchymal cells exhibit distinct mor-
phological and functional characteristics (reviewed inthat mTORC2 becomes active in actin organization only
late in development, or that this mTORC2 function is
required only under specific conditions.
Although Jacinto et al. (2006) focus on the role of
mTORC2 in the regulation of Akt/PKB and Shiota et al.
(2006) focus on the role of mTORC2 in embryogenesis,
the two papers complement and support each other.
Together with the study from Frias et al. (2006), they
provide a major advance in our understanding of the
regulation of cell growth by mTORC2.
Pazit Polak1 and Michael N. Hall1
1Biozentrum
University of Basel
Klingelbergstrasse 70
CH-4056 Basel
Switzerland
Selected Reading
Feng, J., Park, J., Cron, P., Hess, D., and Hemmings, B.A. (2004).
J. Biol. Chem. 279, 41189–41196.
Frias, M.A., Thoreen, C.C., Jaffe, J.D., Schroder, W., Sculley, T.,
Carr, S.A., and Sabatini, D.M. (2006). Curr. Biol. 16, 1865–1870.
Gangloff, Y.G., Mueller, M., Dann, S.G., Svoboda, P., Sticker, M.,
Spetz, J.F., Um, S.H., Brown, E.J., Cereghini, S., Thomas, G., et al.
(2004). Mol. Cell. Biol. 24, 9508–9516.
Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S., Huang,
Q., Qin, J., and Su, B. (2006). Cell 127, in press.
Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Ruegg, M.A., Hall, A.,
and Hall, M.N. (2004). Nat. Cell Biol. 6, 1122–1128.
Murakami, M., Ichisaka, T., Maeda, M., Oshiro, N., Hara, K.,
Edenhofer, F., Kiyama, H., Yonezawa, K., and Yamanaka, S. (2004).
Mol. Cell. Biol. 24, 6710–6718.
Sarbassov, D.D., Ali, S.M., Kim, D.H., Guertin, D.A., Latek, R.R., Erd-
jument-Bromage, H., Tempst, P., and Sabatini, D.M. (2004). Curr.
Biol. 14, 1296–1302.
Sarbassov, D.D., Guertin, D.A., Ali, S.M., and Sabatini, D.M. (2005).
Science 307, 1098–1101.
Shiota, C., Woo, J., Lindner, J., Shelton, K., and Magnuson, M.
(2006). Dev. Cell 11, this issue, 583–589.
Wullschleger, S., Loewith, R., and Hall, M.N. (2006). Cell124, 471–484./j.devcel.2006.09.010
Thiery and Sleeman, 2006). In addition to a specific
gene expression pattern, epithelial cells display apical-
basal polarity manifested in the specific distribution of
cell-surface molecules, organization of cell-cell junc-
tions, polarized organization of the cytoskeleton and
formation of a basal lamina. In contrast to epithelial
cells, mesenchymal cells do not form an organized
cell layer; they do not polarize and can be highly
motile. Epithelial sheets can undergo a transition into
a mesenchyme in a process termed epithelial mesen-
chymal transition (EMT). EMT is characterized by repres-
sion of E-cadherin, gain of vimentin expression, and an
increase in cell motility. The transition from epithelium
to mesenchyme is important for diverse processes in-
volved in tissue formation and organogenesis during
embryonic development (Shook and Keller, 2003).
